vs
Side-by-side financial comparison of Altimmune, Inc. (ALT) and Dianthus Therapeutics, Inc. (DNTH). Click either name above to swap in a different company.
Dianthus Therapeutics, Inc. is the larger business by last-quarter revenue ($284.0K vs $26.0K, roughly 10.9× Altimmune, Inc.). On growth, Altimmune, Inc. posted the faster year-over-year revenue change (420.0% vs -78.6%). Dianthus Therapeutics, Inc. produced more free cash flow last quarter ($-47.1M vs $-67.5M). Over the past eight quarters, Altimmune, Inc.'s revenue compounded faster (128.0% CAGR vs -44.6%).
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies, vaccines, and peptide-based therapies. Its pipeline covers infectious disease prevention, liver disease treatments, and metabolic disorder therapies, serving global biopharmaceutical and healthcare markets while advancing candidates through clinical trials.
Dianthus Therapeutics is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for rare immunological and inflammatory diseases. It advances antibody-based candidates to address unmet needs of severe patients, operating primarily in the U.S. with global development partners.
ALT vs DNTH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.0K | $284.0K |
| Net Profit | — | $-64.4M |
| Gross Margin | — | — |
| Operating Margin | — | -24486.3% |
| Net Margin | — | -22687.3% |
| Revenue YoY | 420.0% | -78.6% |
| Net Profit YoY | -18.0% | -126.6% |
| EPS (diluted) | — | $-1.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.0K | $284.0K | ||
| Q3 25 | $5.0K | $396.0K | ||
| Q2 25 | $5.0K | — | ||
| Q1 25 | $5.0K | $1.2M | ||
| Q4 24 | $5.0K | $1.3M | ||
| Q3 24 | $5.0K | $2.2M | ||
| Q2 24 | $5.0K | $1.9M | ||
| Q1 24 | $5.0K | $874.0K |
| Q4 25 | — | $-64.4M | ||
| Q3 25 | $-19.0M | $-36.8M | ||
| Q2 25 | $-22.1M | — | ||
| Q1 25 | $-19.6M | $-29.5M | ||
| Q4 24 | — | $-28.4M | ||
| Q3 24 | $-22.8M | $-25.2M | ||
| Q2 24 | $-24.6M | $-17.6M | ||
| Q1 24 | $-24.4M | $-13.7M |
| Q4 25 | — | -24486.3% | ||
| Q3 25 | -417180.0% | -10173.7% | ||
| Q2 25 | -458440.0% | — | ||
| Q1 25 | -436300.0% | -2852.7% | ||
| Q4 24 | — | -2406.9% | ||
| Q3 24 | -495340.0% | -1376.6% | ||
| Q2 24 | -534900.0% | -1191.8% | ||
| Q1 24 | -535880.0% | -2041.6% |
| Q4 25 | — | -22687.3% | ||
| Q3 25 | -380280.0% | -9284.1% | ||
| Q2 25 | -442920.0% | — | ||
| Q1 25 | -391500.0% | -2537.5% | ||
| Q4 24 | — | -2144.8% | ||
| Q3 24 | -456900.0% | -1159.0% | ||
| Q2 24 | -492800.0% | -945.1% | ||
| Q1 24 | -487880.0% | -1573.0% |
| Q4 25 | — | $-1.53 | ||
| Q3 25 | $-0.21 | $-0.97 | ||
| Q2 25 | $-0.27 | — | ||
| Q1 25 | $-0.26 | $-0.82 | ||
| Q4 24 | — | $-0.76 | ||
| Q3 24 | $-0.32 | $-0.74 | ||
| Q2 24 | $-0.35 | $-0.51 | ||
| Q1 24 | $-0.34 | $-0.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $273.5M | $404.3M |
| Total DebtLower is stronger | $34.3M | — |
| Stockholders' EquityBook value | $224.9M | $493.4M |
| Total Assets | $279.9M | $530.9M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $273.5M | $404.3M | ||
| Q3 25 | $210.8M | $402.6M | ||
| Q2 25 | $183.1M | — | ||
| Q1 25 | $149.8M | $263.2M | ||
| Q4 24 | $131.9M | $275.2M | ||
| Q3 24 | $139.4M | $281.1M | ||
| Q2 24 | $164.9M | $360.7M | ||
| Q1 24 | $182.0M | $377.0M |
| Q4 25 | $34.3M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $224.9M | $493.4M | ||
| Q3 25 | $185.6M | $546.5M | ||
| Q2 25 | $161.4M | — | ||
| Q1 25 | $142.2M | $328.6M | ||
| Q4 24 | $123.5M | $352.5M | ||
| Q3 24 | $133.4M | $337.9M | ||
| Q2 24 | $152.5M | $358.2M | ||
| Q1 24 | $172.9M | $372.7M |
| Q4 25 | $279.9M | $530.9M | ||
| Q3 25 | $218.4M | $577.4M | ||
| Q2 25 | $190.3M | — | ||
| Q1 25 | $157.3M | $348.6M | ||
| Q4 24 | $139.3M | $374.0M | ||
| Q3 24 | $147.9M | $354.2M | ||
| Q2 24 | $173.3M | $369.0M | ||
| Q1 24 | $188.4M | $382.5M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-67.5M | $-47.0M |
| Free Cash FlowOCF − Capex | $-67.5M | $-47.1M |
| FCF MarginFCF / Revenue | -259792.3% | -16591.9% |
| Capex IntensityCapex / Revenue | 42.3% | 48.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-132.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-67.5M | $-47.0M | ||
| Q3 25 | $-11.9M | $-30.6M | ||
| Q2 25 | $-19.4M | — | ||
| Q1 25 | $-16.8M | $-27.6M | ||
| Q4 24 | $-79.8M | $-27.4M | ||
| Q3 24 | $-27.1M | $-21.3M | ||
| Q2 24 | $-18.1M | $-14.5M | ||
| Q1 24 | $-16.4M | $-14.9M |
| Q4 25 | $-67.5M | $-47.1M | ||
| Q3 25 | — | $-30.6M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-27.7M | ||
| Q4 24 | — | $-27.5M | ||
| Q3 24 | — | $-21.3M | ||
| Q2 24 | — | $-14.5M | ||
| Q1 24 | — | $-15.0M |
| Q4 25 | -259792.3% | -16591.9% | ||
| Q3 25 | — | -7717.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -2377.8% | ||
| Q4 24 | — | -2072.0% | ||
| Q3 24 | — | -980.3% | ||
| Q2 24 | — | -780.7% | ||
| Q1 24 | — | -1713.2% |
| Q4 25 | 42.3% | 48.6% | ||
| Q3 25 | 0.0% | 1.3% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 0.9% | ||
| Q1 24 | — | 3.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
